Hasil Pencarian - Heinz Gisslinger

  • Menampilkan 1 - 18 hasil dari 18
Perbaiki Hasil
  1. 1
    Change in Polycythemia Vera Treatment: Ropeginterferon Alfa-2b in Light of Current Trials

    Change in Polycythemia Vera Treatment: Ropeginterferon Alfa-2b in Light of Current Trials oleh Heinz Gisslinger

    Diterbitkan 2023-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Is ruxolitinib a potentially useful drug in hematological malignancies with RAS pathway hyperactivation?

    Is ruxolitinib a potentially useful drug in hematological malignancies with RAS pathway hyperactivation? oleh Klaus Geissler, Eva Jäger, Agnes Barna, Thamer Sliwa, Paul Knöbl, Ilse Schwarzinger, Heinz Gisslinger, Peter Valent

    Diterbitkan 2016-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Renal outcome in multiple myeloma patients with cast nephropathy: a retrospective analysis of potential predictive values on clinical and renal outcome

    Renal outcome in multiple myeloma patients with cast nephropathy: a retrospective analysis of potential predictive values on clinical and renal outcome oleh Lina Z. Rüsing, Nicolas Kozakowski, Georg Jeryczynski, Lea Vospernik, Julia Riedl, Thomas Reiter, Heinz Gisslinger, Hermine Agis, Maria-Theresa Krauth

    Diterbitkan 2024-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica 2012;97(3):360–5 - Comment

    European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis.... oleh Jürgen Thiele, Attilio Orazi, Hans Michael Kvasnicka, Vito Franco, Emanuela Boveri, Umberto Gianelli, Heinz Gisslinger, Francesco Passamonti, Ayalew Tefferi, Tiziano Barbui

    Diterbitkan 2012-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma

    Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma oleh Heinz Ludwig, Zdenek Adam, Elena Tóthová, Roman Hajek, Boris Labar, Miklós Egyed, Ivan Spicka, Heinz Gisslinger, Johannes Drach, Ingrid Kuhn, Axel Hinke, Niklas Zojer

    Diterbitkan 2010-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Results from HARMONY: an open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis

    Results from HARMONY: an open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in pat... oleh Simon T. Durrant, Arnon Nagler, Paola Guglielmelli, David Lavie, Philipp le Coutre, Heinz Gisslinger, Charles Chuah, Margherita Maffioli, Savita Bharathy, Tuochuan Dong, Monika Wroclawska, Joaquin Martinez Lopez

    Diterbitkan 2019-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    A de novo splice donor mutation in the thrombopoietin gene causes hereditary thrombocythemia in a Polish family

    A de novo splice donor mutation in the thrombopoietin gene causes hereditary thrombocythemia in a Polish family oleh Kun Liu, Robert Kralovics, Zbigniew Rudzki, Barbara Grabowska, Andreas S. Buser, Damla Olcaydu, Heinz Gisslinger, Ralph Tiedt, Patricia Frank, Krzysztof Okoñ, Anthonie P.C. van der Maas, Radek C. Skoda

    Diterbitkan 2008-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Survival expectation after thrombosis and overt-myelofibrosis in essential thrombocythemia and prefibrotic myelofibrosis: a multistate model approach

    Survival expectation after thrombosis and overt-myelofibrosis in essential thrombocythemia and prefibrotic myelofibrosis: a multistate model approach oleh Alessandra Carobbio, Alessandro Maria Vannucchi, Elisa Rumi, Valerio De Stefano, Alessandro Rambaldi, Giuseppe Carli, Maria Luigia Randi, Heinz Gisslinger, Francesco Passamonti, Juergen Thiele, Naseema Gangat, Ayalew Tefferi, Tiziano Barbui

    Diterbitkan 2023-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis

    EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis oleh Alessandro M. Vannucchi, Peter A. W. te Boekhorst, Claire N. Harrison, Guangsheng He, Marianna Caramella, Dietger Niederwieser, Françoise Boyer-Perrard, Minghui Duan, Nathalie Francillard, Betty Molloy, Monika Wroclawska, Heinz Gisslinger

    Diterbitkan 2019-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Inflammation-Based Scores as a Common Tool for Prognostic Assessment in Heart Failure or Cancer

    Inflammation-Based Scores as a Common Tool for Prognostic Assessment in Heart Failure or Cancer oleh Henrike Arfsten, Anna Cho, Suriya Prausmüller, Georg Spinka, Johannes Novak, Georg Goliasch, Philipp E. Bartko, Markus Raderer, Heinz Gisslinger, Gabriela Kornek, Wolfgang Köstler, Guido Strunk, Matthias Preusser, Christian Hengstenberg, Martin Hülsmann, Noemi Pavo

    Diterbitkan 2021-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    P1034: FROM SNAPSHOT TO CONTINUUM: CUMULATIVE TIME IN RESPONSE AS AN EMERGING PROXY FOR THROMBOTIC RISK IN POLYCYTHEMIA VERA

    P1034: FROM SNAPSHOT TO CONTINUUM: CUMULATIVE TIME IN RESPONSE AS AN EMERGING PROXY FOR THROMBOTIC RISK IN POLYCYTHEMIA VERA oleh Heinz Gisslinger, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, Petr Dulicek, Arpad Illes, Halyna Pylypenko, Lylia Sivcheva, Jiří Mayer, Vera Yablokova, Kurt Krejcy, Victoria Empson, Hans C. Hasselbalch, Robert Kralovics, Jean-Jacques Kiladjian

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multi-center, retrospective cohort study

    Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multi-center, retrospective cohort study oleh Marlies Antlanger, Tobias Dust, Thomas Reiter, Alexandra Böhm, Wolfgang W. Lamm, Max Gornicec, Ella Willenbacher, David Nachbaur, Roman Weger, Werner Rabitsch, Susanne Rasoul-Rockenschaub, Nina Worel, Daniel Lechner, Hildegard Greinix, Felix Keil, Heinz Gisslinger, Hermine Agis, Maria-Theresa Krauth

    Diterbitkan 2018-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis

    Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis oleh Christophe Desterke, Christophe Martinaud, Bernadette Guerton, Lisa Pieri, Costanza Bogani, Denis Clay, Frederic Torossian, Jean-Jacques Lataillade, Hans C. Hasselbach, Heinz Gisslinger, Jean-Loup Demory, Brigitte Dupriez, Claude Boucheix, Eric Rubinstein, Sophie Amsellem, Alessandro M. Vannucchi, Marie-Caroline Le Bousse-Kerdilès

    Diterbitkan 2015-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups

    Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups oleh Heinz Gisslinger, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, Viktor Rossiev, Petr Dulicek, Arpad Illes, Halyna Pylypenko, Lylia Sivcheva, Jiri Mayer, Vera Yablokova, Kurt Krejcy, Hans C. Hasselbalch, Robert Kralovics, Jean-Jacques Kiladjian, for the PROUD-PV Study Group

    Diterbitkan 2020-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50 × 10/L to <100 × 10/L) at baseline: the final analysis of EXPAND

    Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50 × 10/L to <100 × 10/L) at baseline: the final analysis of EXPAND oleh Paola Guglielmelli, Jean-Jacques Kiladjian, Alessandro M. Vannucchi, Minghui Duan, Haitao Meng, Ling Pan, Guangsheng He, Srdan Verstovsek, Françoise Boyer, Fiorenza Barraco, Dietger Niederwieser, Ester Pungolino, Anna Marina Liberati, Claire Harrison, Pantelia Roussou, Monika Wroclawska, Divyadeep Karumanchi, Karen Sinclair, Peter A.W. te Boekhorst, Heinz Gisslinger

    Diterbitkan 2022-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  16. 16
    The cancer survival index—A prognostic score integrating psychosocial and biological factors in patients diagnosed with cancer or haematologic malignancies

    The cancer survival index—A prognostic score integrating psychosocial and biological factors in patients diagnosed with cancer or haematologic malignancies oleh Alexander Gaiger, Simone Lubowitzki, Katharina Krammer, Elisabeth L. Zeilinger, Andras Acel, Olivera Cenic, Andrea Schrott, Matthias Unseld, Anahita Paula Rassoulian, Cathrin Skrabs, Peter Valent, Heinz Gisslinger, Christine Marosi, Matthias Preusser, Gerald Prager, Gabriela Kornek, Robert Pirker, Günther G. Steger, Rupert Bartsch, Markus Raderer, Ingrid Simonitsch‐Klupp, Renate Thalhammer, Christoph Zielinski, Ulrich Jäger

    Diterbitkan 2022-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  17. 17
    Complex patterns of chromosome 11 aberrations in myeloid malignancies target CBL, MLL, DDB1 and LMO2.

    Complex patterns of chromosome 11 aberrations in myeloid malignancies target CBL, MLL, DDB1 and LMO2. oleh Thorsten Klampfl, Jelena D Milosevic, Ana Puda, Andreas Schönegger, Klaudia Bagienski, Tiina Berg, Ashot S Harutyunyan, Bettina Gisslinger, Elisa Rumi, Luca Malcovati, Daniela Pietra, Chiara Elena, Matteo Giovanni Della Porta, Lisa Pieri, Paola Guglielmelli, Christoph Bock, Michael Doubek, Dana Dvorakova, Nada Suvajdzic, Dragica Tomin, Natasa Tosic, Zdenek Racil, Michael Steurer, Sonja Pavlovic, Alessandro M Vannucchi, Mario Cazzola, Heinz Gisslinger, Robert Kralovics

    Diterbitkan 2013-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  18. 18
    Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies

    Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies oleh Ruben A. Mesa, Jean-Jacques Kiladjian, Srdan Verstovsek, Haifa Kathrin Al-Ali, Jason Gotlib, Heinz Gisslinger, Richard Levy, Andres Siulnik, Vikas Gupta, Mahmudul Khan, John F. DiPersio, Mari McQuitty, John V. Catalano, Deborah S. Hunter, Laurent Knoops, Michael Deininger, Francisco Cervantes, Carole Miller, Alessandro M. Vannucchi, Richard T. Silver, Tiziano Barbui, Moshe Talpaz, Giovanni Barosi, Elliott F. Winton, Estella Mendeson, Jimmie H. Harvey, Murat O. Arcasoy, Elizabeth Hexner, Roger M. Lyons, Ronald Paquette, Azra Raza, William Sun, Victor Sandor, Hagop M. Kantarjian, Claire Harrison

    Diterbitkan 2014-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: